• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

China CDC Wkly . SARS-CoV-2 Surveillance Through China Influenza Surveillance Information System - China, December 1, 2022 to February 12, 2023

tetano

Editor, Senior Moderator
China CDC Wkly


. 2023 Feb 17;5(7):152-158.
doi: 10.46234/ccdcw2023.027.
SARS-CoV-2 Surveillance Through China Influenza Surveillance Information System - China, December 1, 2022 to February 12, 2023


Xiaoxu Zeng[SUP] 1 [/SUP], Yiran Xie[SUP] 1 2 [/SUP], Xiaokun Yang[SUP] 3 [/SUP], Zhibin Peng[SUP] 3 [/SUP], Jing Tang[SUP] 1 2 [/SUP], Lei Yang[SUP] 1 [/SUP], Shuxia Lin[SUP] 1 [/SUP], Jun Han[SUP] 1 [/SUP], Yanping Zhang[SUP] 3 [/SUP], Dayan Wang[SUP] 1 [/SUP]



Affiliations

Abstract

Introduction: The World Health Organization (WHO) proposed using influenza surveillance systems to carry out coronavirus disease 2019 (COVID-19) surveillance due to the similarity between the two diseases in some respiratory symptoms. To assess the prevalence of COVID-19, we analyzed the influenza-like illness (ILI) and positive rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detections in ILI patients reported to the influenza Surveillance Information System (CNISIS) since late 2022.
Methods: Data related to ILI were reported by national surveillance sentinel hospitals. Positive testing for SARS-CoV-2 and influenza viruses was conducted using real-time reverse transcription polymerase chain reaction (rRT-PCR) detection by the national influenza surveillance network laboratories. Surveillance data were reported to CNISIS.
Results: Beginning on December 12, 2022 (Week 50), the ILI percentage increased dramatically, peaking in Week 51 at 12.1%. Subsequently, the ILI percentage began to decline rapidly from Week 52, 2022, and by Week 6, 2023 (February 6-12), the ILI and ILI percentage had returned to the levels observed at the beginning of December 2022. From December 1, 2022 to February 12, 2023, 115,844 specimens were tested for both SARS-CoV-2 and influenza virus. Of these, 30,381 (26.2%) were positive for SARS-CoV-2 and 1,763 (1.5%) were positive for influenza virus. The positive rate of SARS-CoV-2 tests peaked at 74.1% around December 23 and 25.
Conclusions: Sentinel-based surveillance, previously established for influenza, is an effective way to track the circulation trend of SARS-CoV-2 during community-level epidemics. There was no co-prevalence of SARS-CoV-2 and influenza virus during the outbreak of SARS-CoV-2, even during the winter influenza season. However, it is important to remain vigilant for the potential rise of influenza activities following the COVID-19 epidemic.

Keywords: COVID-19; ILI; SARS-CoV-2; surveillances.
 
Back
Top Bottom